ArticleBMC cancer2020

DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.

Xuemin Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.